new version V2017

Palbociclib CDK (cyclin-dependent kinase) inhibitor

PD-0332991 - PD0332991 - PD 0332991 - Ibrance - palbociclib      

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced breast cancer (metastatic)

PALOMA 3, 2015palbociclib + fulvestrantfulvestrant alone2nd line Low risk of bias ConclusiveNCT01942135
PALOMA 1/TRIO-18, 2015palbociclib + letrozoleletrozole alone Exploratory SuggestingNCT00721409
PALOMA-2, 2016palbociclib + letrozoleletrozole alonefirst line Low risk of bias ConclusiveNCT01740427
PEARL ongoing palbociclib + exemestanecapecitabine Risk of bias - NCT02028507
PALOMA-4 ongoing palbociclib + letrozoleletrozole alone Low risk of bias - NCT02297438
PENELOPE-B ongoing palbociclibplacebo Low risk of bias - NCT01864746